Clinical Trial News Archive - May 2024
May 1, 2024
- NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
- Scientists Discover How an Essential Nutrient Enters the Brain
May 2, 2024
- Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder
- Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism
May 3, 2024
- AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
- Phase 2 data for Erleada plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer results published
May 6, 2024
- NRx Pharmaceuticals Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
- Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
- EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of Duravyu in Non-Proliferative Diabetic Retinopathy
May 7, 2024
May 8, 2024
- Faster Approach for Starting Extended-Release Naltrexone to Treat Opioid Use Disorder Shown Effective
- Bayer to Unveil Late-Breaking Data from Phase III OASIS 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
- Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
May 9, 2024
May 13, 2024
- Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
- Geisinger enrolls first patient in amyloid cardiomyopathy trial
May 14, 2024
May 15, 2024
- First Patient Dosed in Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer
- Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
May 16, 2024
- With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
- Adverse Social Determinants of Health Linked to Treatment-Resistant Hypertension in Black Americans
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug BIIB105 in Amyotrophic Lateral Sclerosis
- Elinzanetant Significantly Reduces Frequency and Severity of Moderate to Severe Hot Flashes Associated with Menopause
- SUPERNOVA Phase III trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing COVID-19 in Immunocompromised Patient Population
Clinical trial results archive
- 2024
- January, February, March, April, May
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.